![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Acino gains the rights to commercialise Allecra’s antibiotic drug Exblifep (cefepime/enmetazobactam) within the Republic of South Africa and the member states of the GCC alliance.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Exblifep
Highest Development Status: Phase IVProduct Type: Small molecule
Recipient: Acino Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 25, 2024
Details:
Exblifep (cefepime/enmetazobactam) has been designed to combat anti-microbial resistance in gram-negative bacteria. It is indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Exblifep
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
EXBLIFEP (cefepime/enmetazobactam) has been designed to combat anti-microbial resistance in gram-negative bacteria, especially resistance mediated by Extended Spectrum Beta Lactamases and which is investigated in patients with complicated urinary tract infections.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Exblifep
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Among patients with cUTI caused by gram-negative pathogens, cefepime/enmetazobactam, compared with piperacillin/tazobactam, met criteria for noninferiority as well as superiority with respect to the primary outcome of clinical cure and microbiological eradication.
Lead Product(s): Enmetazobactam,Cefepime
Therapeutic Area: Infections and Infectious Diseases Product Name: AAI101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam.
Lead Product(s): Enmetazobactam,Cefepime
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2020